Delivery Order SPE2DR25D3004-SPE2DR26FXLU6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a ceiling value of $5,252.73. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for Ondansetron HCl 4 mg tablets (30-count) valued at $1,689.89. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is scheduled for ultimate completion by October 24, 2025,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Ondansetron HCl 4 mg tablets in unit dose packaging (100-count), valued at $3,288.64 with a firm fixed price structure. The contract, which is a non-set-aside competitive award, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30 units, with a contract ceiling value of $3,280.33. This is a firm fixed price delivery order with an ultimate completion date of September 24, 2025, and represents a non-competitive, open competition award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units. This is a firm fixed-price delivery order with a ceiling value of $9,303.33 and an ultimate completion date of August 20, 2025. The contract is non-competitive and represents a direct purchase under AmerisourceBergen's existing indefinite delivery contract framework. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count) with a contract value of $2,164.46. The award was made on September 22, 2025, with an ultimate completion date of September 23, 2025, under a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,371.12 to supply Ondansetron HCL 4 mg tablets in a quantity of 30 units. This delivery order, issued on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a firm fixed-price transaction with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count packaging) with a contract value of $3,436.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a contract ceiling value of $9,131.84. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting the contractor's...
- SPE2DR25D3004Indefinite Delivery Contract
- SPE2DR25D3004-SPE2DR26FXLU6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30 units, with a contract ceiling value of $7,043.20 and an ultimate completion date of November 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of pharmaceuticals and medical supplies to support military and veteran healthcare systems. The Ondansetron HCL delivery under this order supports the company's role in providing essential medications across multiple therapeutic domains to the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 11/13/25 |